AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22159768 — intervention group
Group type: EXPERIMENTAL
Intervention: NutriAlz program (intervention group)
Number of subjects: 946
Study 22159768 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 946
Study 18707785 — intervention group
Group type: EXPERIMENTAL
Intervention: Low boost dose of 10 Gy
Number of subjects: 251
Study 18707785 — intervention group
Group type: COMPARATOR
Intervention: High boost dose of 26 Gy
Number of subjects: 251
Study 16937967 — intervention group
Group type: EXPERIMENTAL
Intervention: OSt (resisted-sprint training)
Number of subjects: 37
Study 16937967 — intervention group
Group type: EXPERIMENTAL
Intervention: OSp (assisted-sprint training)
Number of subjects: 37
Study 16937967 — intervention group
Group type: COMPARATOR
Intervention: C (control group)
Number of subjects: 37
Study 15265250 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg
Number of subjects: 2413
Study 15265250 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg
Number of subjects: 2413
Study 11735866 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-day course of i.v. ampicillin, gentamicin sulfate, and clindamycin (n = 10)
Number of subjects: 26
Study 11735866 — intervention group
Group type: COMPARATOR
Intervention: Short course of i.v. ampicillin, gentamicin, and clindamycin followed by p.o. amoxicillin and clavulanate potassium plus metronidazole (n = 16)
Number of subjects: 26
Study 11735866 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 11735866 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion to oral therapy
Number of subjects: 26
Study 11367661 — intervention group
Group type: EXPERIMENTAL
Intervention: Neiyixiao Recipe (NYXR)
Number of subjects: 103
Study 11367661 — intervention group
Group type: COMPARATOR
Intervention: danazol (Control)
Number of subjects: 103
Study 8172790 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine (NVB) 30 mg/m2/week
Number of subjects: 231
Study 8172790 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine (NVB) 30 mg/m2/week plus Cisplatin (DDP) 80 mg/m2/3 weeks
Number of subjects: 231
Study 3266254 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire-first group (completed questionnaire before biochemical validation)
Number of subjects: 160
Study 3266254 — intervention group
Group type: COMPARATOR
Intervention: Pipeline-first group (samples collected before completing questionnaire)
Number of subjects: 160
Study 31623096 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined warm up (CWU)
Number of subjects: 28
Study 31623096 — intervention group
Group type: COMPARATOR
Intervention: Global warm up (GWU)
Number of subjects: 28
Study 29033296 — intervention group
Group type: EXPERIMENTAL
Intervention: Prochlorperazine and diphenhydramine
Number of subjects: 54
Study 29033296 — intervention group
Group type: COMPARATOR
Intervention: Ketamine and ondansetron
Number of subjects: 54
Study 26721229 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee joint mobilization (6 minutes)
Number of subjects: 40
Study 26721229 — intervention group
Group type: COMPARATOR
Intervention: Manual cutaneous input only (control)
Number of subjects: 40
Study 25632741 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvia Miltiorrhiza (1 g each time, three times per day till one month after PCI)
Number of subjects: 52
Study 25632741 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy (control group)
Number of subjects: 52
Study 22309178 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey mouthwash
Number of subjects: 66
Study 22309178 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Chlorhexidine gluconate rinse
Number of subjects: 66
Study 22309178 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey rinse
Number of subjects: 66
Study 22309178 — intervention group
Group type: COMPARATOR
Intervention: 0.2% Chlorhexidine rinse
Number of subjects: 66
Study 22309178 — intervention group
Group type: COMPARATOR
Intervention: Saline rinse
Number of subjects: 66
Study 19908937 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 0
Study 19908937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17392122 — intervention group
Group type: EXPERIMENTAL
Intervention: Black rice pigment fraction (BRF) supplementation (10 grams for 6 months)
Number of subjects: 60
Study 17392122 — intervention group
Group type: COMPARATOR
Intervention: White rice pigment fraction (WRF) supplementation (10 grams for 6 months)
Number of subjects: 60
Study 15124679 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan/fludarabine (3 x 10 g/m2 of treosulfan with 5 x 30 mg/m2 of fludarabine)
Number of subjects: 55
Study 15124679 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan (escalated from 3 x 10 to 3 x 12 and 3 x 14 g/m2)
Number of subjects: 55
Study 15124679 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan
Number of subjects: 55
Study 10865808 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for the first six months
Number of subjects: 23
Study 10865808 — intervention group
Group type: COMPARATOR
Intervention: placebo for the first six months
Number of subjects: 23
Study 10865808 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for the second six months
Number of subjects: 23
Study 10865808 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant growth hormone (rhGH) for both groups in the second six months
Number of subjects: 23
Study 9277247 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids alone
Number of subjects: 78
Study 9277247 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual aids plus an Advanced Organizer
Number of subjects: 78
Study 9277247 — intervention group
Group type: COMPARATOR
Intervention: Control group (no visual aids)
Number of subjects: 78
Study 8222667 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive drug treatment
Number of subjects: 4736
Study 8222667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 3512394 — intervention group
Group type: EXPERIMENTAL
Intervention: Human insulin
Number of subjects: 30
Study 3512394 — intervention group
Group type: COMPARATOR
Intervention: Porcine insulin
Number of subjects: 30
Study 3446162 — intervention group
Group type: EXPERIMENTAL
Intervention: Low pH intravenous immunoglobulin
Number of subjects: 18
Study 3446162 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous immunoglobulin
Number of subjects: 18
Study 30475043 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training program on pediatric medical traumatic stress and trauma-informed care (15-min online training program)
Number of subjects: 71
Study 30475043 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training initially)
Number of subjects: 71
Study 28620924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam premedication
Number of subjects: 135
Study 28620924 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam + Digital Video-Disk
Number of subjects: 135
Study 28620924 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Video-Disk alone
Number of subjects: 135
Study 28620924 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 135
Study 25496615 — intervention group
Group type: EXPERIMENTAL
Intervention: Postnatal psychoeducation programme
Number of subjects: 122
Study 25496615 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 122
Study 23347874 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support, financial reimbursement, and internet-based counselling
Number of subjects: 120
Study 23347874 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 120
Study 21649612 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (500 mg/day × 14 days/month × 3 months)
Number of subjects: 16
Study 21649612 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18022183 — intervention group
Group type: EXPERIMENTAL
Intervention: Explaining to mom
Number of subjects: 54
Study 18022183 — intervention group
Group type: EXPERIMENTAL
Intervention: Explaining to themselves
Number of subjects: 54
Study 18022183 — intervention group
Group type: COMPARATOR
Intervention: Repeating the solutions
Number of subjects: 54
Study 16808575 — intervention group
Group type: EXPERIMENTAL
Intervention: Forsus Nitinol Flat Spring (FNFS)
Number of subjects: 48
Study 16808575 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasper Jumper (JJ)
Number of subjects: 48
Study 16808575 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48
Study 15296685 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to classical music
Number of subjects: 75
Study 15296685 — intervention group
Group type: COMPARATOR
Intervention: Silence (Control)
Number of subjects: 75
Study 15296685 — intervention group
Group type: EXPERIMENTAL
Intervention: Listening to jazz or pop music
Number of subjects: 75
Study 10862530 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxic training
Number of subjects: 34
Study 10862530 — intervention group
Group type: COMPARATOR
Intervention: Normoxic training
Number of subjects: 34
Study 9242843 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 229
Study 9242843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 9242843 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 229
Study 8290450 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone-iodine (PVP-I) ointment
Number of subjects: 129
Study 8290450 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 129
Study 3771765 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial laparotomy drapes with 3-(trimethoxysilyl)propyldimethyloctadecyl ammonium chloride
Number of subjects: 110
Study 3771765 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-antimicrobial segments of the drape)
Number of subjects: 110
Study 30222643 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG) preparation
Number of subjects: 43
Study 30222643 — intervention group
Group type: COMPARATOR
Intervention: Fasting only (FO) preparation
Number of subjects: 43
Study 29618327 — intervention group
Group type: EXPERIMENTAL
Intervention: Young & Active web-based intervention to increase physical activity
Number of subjects: 21
Study 27003272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids + Facial Neuromuscular Training (C + FNT)
Number of subjects: 73
Study 27003272 — intervention group
Group type: COMPARATOR
Intervention: Facial Neuromuscular Training (FNT)
Number of subjects: 73
Study 27003272 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Number of subjects: 73
Study 25538086 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) assay (Erenna, 99th percentile 9 pg/ml)
Number of subjects: 1807
Study 24073978 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 23 mg/day
Number of subjects: 1400
Study 24073978 — intervention group
Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 1400
Study 24073978 — intervention group
Group type: EXPERIMENTAL
Intervention: SIB-8
Number of subjects: 1400
Study 24073978 — intervention group
Group type: EXPERIMENTAL
Intervention: Full SIB
Number of subjects: 1400
Study 24073978 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SIB scales
Number of subjects: 1400
Study 20493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan 40 mg
Number of subjects: 308
Study 20493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8 mg
Number of subjects: 308
Study 20493430 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 80 mg
Number of subjects: 308
Study 18179495 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced counseling and support (six sessions of individual and family counseling, support group participation, and continuous availability of ad hoc telephone counseling)
Number of subjects: 406
Study 18179495 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 406
Study 16854276 — intervention group
Group type: EXPERIMENTAL
Intervention: CHB patients
Number of subjects: 120
Study 16854276 — intervention group
Group type: EXPERIMENTAL
Intervention: CHB patients with HBV DNA > 10^7 copies/ml
Number of subjects: 120
Study 16854276 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent phase
Number of subjects: 120
Study 16854276 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 120
Study 12727933 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement-dose r‐metHuLeptin during fasting
Number of subjects: 8
Study 12727933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 12727933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose r‐metHuLeptin
Number of subjects: 8
Study 12727933 — intervention group
Group type: COMPARATOR
Intervention: Baseline fed state
Number of subjects: 8
Study 10733492 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of MOPP/ABV
Number of subjects: 559
Study 10733492 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of MOPP/ABV plus RTx
Number of subjects: 559
Study 10733492 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 cycles of ABVPP
Number of subjects: 559
Study 10733492 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 cycles of ABVPP plus RTx
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTx)
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RTx)
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTx) after MOPP/ABV
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RTx) after MOPP/ABV
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (CTx) after ABVPP
Number of subjects: 559
Study 10733492 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RTx) after ABVPP
Number of subjects: 559
Study 8958889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion at 20-80 micrograms/kg/min
Number of subjects: 8
Study 8958889 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 8
Study 8958889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion with oxygen administration
Number of subjects: 8
Study 8958889 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine infusion
Number of subjects: 8
Study 1550279 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane with 70% N2O in oxygen (O2)
Number of subjects: 50
Study 1550279 — intervention group
Group type: COMPARATOR
Intervention: isoflurane in an air/O2 mixture
Number of subjects: 50
Study 2868581 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg at bedtime for 6 months
Number of subjects: 344
Study 2868581 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg at bedtime for 12 months
Number of subjects: 344
Study 2868581 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 344
Study 2868581 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 months
Number of subjects: 344
Study 31069549 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified radical hysterectomy (mRH)
Number of subjects: 1335
Study 31069549 — intervention group
Group type: COMPARATOR
Intervention: Simple hysterectomy (SH)
Number of subjects: 1335
Study 28639216 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 µg selexipag (Treatment A)
Number of subjects: 0
Study 28639216 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 paediatric tablets of 50 µg selexipag (Treatment B)
Number of subjects: 0
Study 27676259 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU communication facilitator
Number of subjects: 135
Study 24412554 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg Nigella sativa L. seeds (NS) once daily for four weeks
Number of subjects: 48
Study 24412554 — intervention group
Group type: COMPARATOR
Intervention: 500 mg placebo once daily for four weeks
Number of subjects: 48
Study 24568073 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 fatty acids (635 mg EPA, 195 mg DHA)
Number of subjects: 103
Study 24568073 — intervention group
Group type: COMPARATOR
Intervention: Placebo (olive oil capsules)
Number of subjects: 103
Study 19551236 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 707
Study 17227907 — intervention group
Group type: EXPERIMENTAL
Intervention: 37.5 mg of venlafaxine (low‐dose study)
Number of subjects: 77
Study 17227907 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg of venlafaxine (high‐dose study)
Number of subjects: 77
Study 17227907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 77
Study 15138687 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity counselling (n=35)
Number of subjects: 70
Study 15138687 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=35)
Number of subjects: 70
Study 11593906 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal treatment for localized disease (n=223)
Number of subjects: 642
Study 11593906 — intervention group
Group type: COMPARATOR
Intervention: Primary treatment with radiotherapy (n=75) or radical prostatectomy (n=2) +/- hormonal treatment (n=77)
Number of subjects: 642
Study 9442158 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactate measurements
Number of subjects: 341
Study 9442158 — intervention group
Group type: COMPARATOR
Intervention: pH analysis
Number of subjects: 341
Study 7913949 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium aspartate (15 mmol/day for 8 weeks)
Number of subjects: 39
Study 7913949 — intervention group
Group type: COMPARATOR
Intervention: Placebo (8 weeks)
Number of subjects: 39
Study 2656133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (Voltaren)
Number of subjects: 60
Study 2656133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2656133 — intervention group
Group type: COMPARATOR
Intervention: Papaverine
Number of subjects: 60
Study 2656133 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac sodium (Voltaren) for low back pain (LBP)
Number of subjects: 60
Study 31127284 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptom-based screening
Number of subjects: 1017
Study 31127284 — intervention group
Group type: COMPARATOR
Intervention: TST-based screening
Number of subjects: 1017
Study 30113350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (bolus 0.2 mg/kg over 30 min followed by 0.12 mg/kg/h for 24 h)
Number of subjects: 129
Study 30113350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 129
Study 30113350 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine infusion (in opioid-naïve patients)
Number of subjects: 129
Study 30113350 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in opioid-naïve patients)
Number of subjects: 129
Study 28485415 — intervention group
Group type: EXPERIMENTAL
Intervention: Prebiotic mix in yogurt (one yogurt per day for 12 days)
Number of subjects: 24
Study 28485415 — intervention group
Group type: COMPARATOR
Intervention: Control group (yogurt without prebiotic mix)
Number of subjects: 24
Study 26605505 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC)
Number of subjects: 109
Study 26605505 — intervention group
Group type: COMPARATOR
Intervention: Ritonavir-boosted atazanavir (ATV/r) plus raltegravir (RAL)
Number of subjects: 109
Study 25181784 — intervention group
Group type: EXPERIMENTAL
Intervention: Action plan intervention for self-management
Number of subjects: 19
Study 22686416 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 12537
Study 22686416 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 12537
Study 20634623 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced air warmer applied for 45-90 min before surgery
Number of subjects: 40
Study 17617382 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal application of 24 IU oxytocin
Number of subjects: 0
Study 17617382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16651205 — intervention group
Group type: EXPERIMENTAL
Intervention: Testim 1% (5 g)
Number of subjects: 48
Study 16651205 — intervention group
Group type: COMPARATOR
Intervention: AndroGel 1% (5 g)
Number of subjects: 48
Study 12147926 — intervention group
Group type: EXPERIMENTAL
Intervention: Telmisartan
Number of subjects: 0
Study 12147926 — intervention group
Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 0
Study 12147926 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan and Valsartan
Number of subjects: 0
Study 9820705 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) treatment
Number of subjects: 40
Study 9820705 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 9502783 — intervention group
Group type: EXPERIMENTAL
Intervention: L-2-Oxothiazolidine-4-carboxylic acid (OTC) 4.5 g
Number of subjects: 48
Study 9502783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 1662578 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (0.6 ng/min)
Number of subjects: 14
Study 1662578 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine vasopressin (1.8 ng/min)
Number of subjects: 14
Study 1662578 — intervention group
Group type: COMPARATOR
Intervention: Control (Saline)
Number of subjects: 14
Study 1662578 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II
Number of subjects: 14
Study 6922470 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing social support program
Number of subjects: 47
Study 6922470 — intervention group
Group type: COMPARATOR
Intervention: Medication clinic
Number of subjects: 47
Study 30894279 — intervention group
Group type: EXPERIMENTAL
Intervention: serlopitant, 5 mg, orally once daily for 8 weeks
Number of subjects: 128
Study 30894279 — intervention group
Group type: COMPARATOR
Intervention: placebo, orally once daily for 8 weeks
Number of subjects: 128